Showing results (81-90 of 430) with videos related to

Sort By:
Pageof 43
European Journal of Heart Failure|February 19, 2019
Klotho, fibroblast growth factor-23, and the renin-angiotensin system - an analysis from the PEACE trialBrian A Bergmark, Jacob A Udell, David A Morrow, et al.
Circulation. Heart Failure|May 31, 2014
Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fractionNatalie A Bello, Brian Claggett, Akshay S Desai, et al.
European Journal of Heart Failure|October 31, 2009
Adherence to medication according to sex and age in the CHARM programmeBradi B Granger, Inger Ekman, Christopher B Granger, et al.
Stroke|January 29, 2015
Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failureRoopinder K Sandhu, Stefan H Hohnloser, Marc A Pfeffer, et al.
The American Journal of Cardiology|July 7, 2009
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)Robert M Califf, Yuliya Lokhnygina, Eric J Velazquez, et al.
European Journal of Heart Failure|March 22, 2017
Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fractionTor Biering-Sørensen, Sanjiv J Shah, Inder Anand, et al.
American Heart Journal|March 29, 2008
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndromeLisa M Mielniczuk, Marc A Pfeffer, Eldrin F Lewis, et al.
European Journal of Heart Failure|December 2, 2017
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failureEmil Wolsk, Brian Claggett, Lars Køber, et al.
European Journal of Heart Failure|July 19, 2016
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programmeKevin Damman, Scott D Solomon, Marc A Pfeffer, et al.
JAMA|September 18, 2003
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trialChristopher M O'Connor, Michael W Dunne, Marc A Pfeffer, et al.
Pageof 43